Tearsheet
Investment Highlights Market Valuation Price Chart About LLY Interactive Breakdown Better Bets vs. LLY Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Eli Lilly (LLY)

Market Price (10/20/2025): $803.08 | Market Cap: $721.1 Bil
Sector: Health Care | Industry: Pharmaceuticals

Eli Lilly (LLY)

Market Price (10/20/2025): $803.08
Market Cap: $721.1 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%		 Weak multi-year price returns
2Y Excs Rtn is -20%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 66x, P/EPrice/Earnings or Price/(Net Income) is 52x
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, CFO LTM is 11 Bil		  
3 Low stock price volatility
Vol 12M is 41%		  
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, CFO LTM is 11 Bil
3 Low stock price volatility
Vol 12M is 41%
4 Weak multi-year price returns
2Y Excs Rtn is -20%
5 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 66x, P/EPrice/Earnings or Price/(Net Income) is 52x

Market Valuation & Key Metrics

LLYS&P 500
REVENUE GROWTHVERY GOOD
Rev LTM ($ Bil)53.3
Rev Chg Q37.6%6.1%
Rev Chg LTM36.8%5.2%
Rev Chg 3Y Avg23.4%5.4%
PROFITABILITYVERY GOOD
Op Inc LTM ($ Bil)22.9
Op Mgn LTM43.0%18.6%
CFO LTM ($ Bil)10.9
CFO/Rev LTM20.5%20.4%
Net Inc LTM ($ Bil)13.8
Net Inc Mgn25.9%12.7%
VALUATIONVERY HIGH
P/S13.53.2
P/CFO65.915.9
P/FCF-14,364.320.7
P/E52.324.0
STABILITYGOOD
Debt/Equity0.060.22
Cash/Assets0.040.07

LLY Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
LLY Return31%66%34%61%33%5%556%
Peers Return-3%15%13%-14%0%-8%-1%
S&P 500 Return16%27%-19%24%23%13%106%

Monthly Win Rates [3]
LLY Win Rate50%58%75%58%58%56% 
Peers Win Rate35%42%48%27%45%47% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
LLY Max Drawdown-9%-3%-15%-15%0%-19% 
Peers Max Drawdown-21%-7%-9%-19%-10%-21% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: MRK, PFE, BMY, BDX, BGM. See LLY Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/17/2025 (YTD)

Downturns Compared

Unique KeyEventLLYS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-18.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven23.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven78 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-22.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven29.6%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven47 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-18.5%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven22.7%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven154 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-54.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven120.5%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1873 days1480 days


How Low Can It Go?

Eli Lilly's stock fell -18.7% during the 2022 Inflation Shock from a high on 8/17/2021. A -18.7% loss requires a 23.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Better Bets than Eli Lilly (LLY)

 LLYBetter Performance than LLY
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM36.8%KNSA (56.2%), ALVO (82.6%), ANIP (38.7%), AVDL (132.3%), HROW (47.7%)
Rev Chg 3Y Avg23.4%ACAD (27.9%), KNSA (96.3%), ALVO (150.9%), ANIP (44.2%), HROW (39.8%)
Op Mgn LTM43.0%INVA (47.7%), SIGA (56.3%)
CFO/Rev LTM20.5%JNJ (25.4%), MRK (29.1%), PFE (23.8%), BMY (30.0%), ZTS (31.2%)
FCF/Rev LTM-0.1%JNJ (18.1%), MRK (23.1%), PFE (19.5%), BMY (27.5%), ZTS (23.6%)
Total Yield2.6%JNJ (7.5%), MRK (11.5%), PFE (12.9%), BMY (11.7%), ZTS (5.4%)
 LLYBetter Performance than LLY
MetricValueAll Other Sectors
Rev Chg LTM36.8%NVDA (71.6%), PLTR (38.8%), MU (48.9%), APP (48.2%), APH (40.5%)
Rev Chg 3Y Avg23.4%NVDA (92.0%), AVGO (24.0%), PLTR (25.7%), SHOP (26.0%), APP (23.7%)
Op Mgn LTM43.0%NVDA (58.1%), MSFT (45.6%), V (66.5%), MA (58.0%), MCD (46.1%)
CFO/Rev LTM20.5%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM-0.1%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield2.6%MSFT (3.3%), AAPL (3.0%), GOOGL (4.1%), AMZN (3.1%), META (4.0%)
 Best Bets In Health Care Sector
 LLYRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA UHS
What You Pay           
P/E52.215.414.612.014.114.410.614.711.917.110.4
P/EBIT40.68.111.510.39.69.226.110.010.09.37.2
What You Get           
Rev Chg Q37.6%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%9.6%
Rev Chg LTM36.8%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%9.6%
Rev Chg 3Y Avg23.4%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%8.1%
FCF/Rev 3Y Avg0.5%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%4.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Eli Lilly Earnings Notes  
2Eli Lilly Stock Up 5.2%, Buy Or Wait?Return 
3LLY Pricing Powerhouse Now 37% Cheaper - Buy?Actionable 
4LLY Capital Return Hits $100 Bil in 10 Years  
5A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy?Actionable 
6Leadership, Pricing Power, and a 37% Cheaper Tag on LLYActionable 
7Leadership, Pricing Power, and a 37% Cheaper Tag on LLYActionable 
8A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy?Actionable 
9Dominance at a Discount: Does LLY's Valuation Pullback Offer Invesment Opportunity?Actionable 
10When Market Leadership Goes on Sale: Does LLY's 37% Valuation Reset Make It A Buy?Actionable 
11ARTICLES  
12A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly stock A Buy? October 9th, 2025
13High Margins, Lower Price: Is This Eli Lilly stock’s Buying Window? October 8th, 2025
14Leadership, Pricing Power, and a 30% Cheaper Tag on LLY October 7th, 2025
15Leadership, Pricing Power, and a 30% Cheaper Tag on LLY October 4th, 2025
16A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy? October 3rd, 2025
Title
0DASHBOARDS
1A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly stock A Buy?
2High Margins, Lower Price: Is This Eli Lilly stock’s Buying Window?
3Leadership, Pricing Power, and a 30% Cheaper Tag on LLY
4Leadership, Pricing Power, and a 30% Cheaper Tag on LLY
5A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy?
6ARTICLES
7Eli Lilly Earnings Notes
8Eli Lilly Stock Up 5.2%, Buy Or Wait?
9LLY Pricing Powerhouse Now 37% Cheaper - Buy?
10LLY Capital Return Hits $100 Bil in 10 Years
11A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy?
12Leadership, Pricing Power, and a 37% Cheaper Tag on LLY
13Leadership, Pricing Power, and a 37% Cheaper Tag on LLY
14A Pricing Powerhouse, Now 37% Cheaper: Is LLY A Buy?
15Dominance at a Discount: Does LLY's Valuation Pullback Offer Invesment Opportunity?
16When Market Leadership Goes on Sale: Does LLY's 37% Valuation Reset Make It A Buy?

Trade Ideas

Select past ideas related to LLY. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-4.4%-4.4%-8.0%
LLY_5312025_Monopoly_xInd_xCD_Getting_Cheaper05312025LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		9.1%9.1%-15.2%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-4.4%-4.4%-8.0%
LLY_5312025_Monopoly_xInd_xCD_Getting_Cheaper05312025LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		9.1%9.1%-15.2%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines256.7%146.9%
2NVTSNavitas Semiconductor78.1%310.6%
3SSIISS Innovations International40.1%23.4%
4FLNCFluence Energy40.0%15.4%
5BTDRBitdeer Technologies35.1%10.8%
6MVSTMicrovast34.6%181.6%
7POWIPower Integrations31.3%-25.4%
8CCOClear Channel Outdoor30.8%24.1%
9IRONDisc Medicine28.7%41.9%
10BEBloom Energy28.4%402.0%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1SOCSable Offshore-35.8%-48.4%
2SRRKScholar Rock-29.2%-35.4%
3AIVApartment Investment & Management-28.3%-9.0%
4ALABAstera Labs-22.5%20.6%
5BYRNByrna Technologies-19.7%-26.6%
6BWINBaldwin Insurance-19.5%-40.3%
7ONDSOndas-17.5%197.3%
8URGUr-Energy-17.4%40.0%
9IIINInsteel Industries-16.4%14.6%
10LIFLife360-16.0%112.3%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1160.2%365.5%
2PRAXPraxis Precision Medicines320.1%146.9%
3QUREuniQure293.5%228.4%
4FLNCFluence Energy131.4%15.4%
5CLPTClearPoint Neuro123.6%65.0%
6NVTSNavitas Semiconductor117.8%310.6%
7LACLithium Americas110.9%128.6%
8ASTSAST SpaceMobile101.5%295.7%
9BETRBetter Home & Finance97.8%610.2%
10GRALGRAIL97.0%337.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-50.9%-48.4%
2FLYFirefly Aerospace-41.7% 
3PGYPagaya Technologies-39.5%185.3%
4UPWheels Up Experience-37.1%-6.7%
5ALABAstera Labs-36.6%20.6%
6VGVenture Global-35.8% 
7USNAUsana Health Sciences-32.3%-41.8%
8UPSTUpstart-31.7%-24.5%
9DOMODomo-30.8%73.6%
10TROXTronox-30.6%-63.2%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines256.7%146.9%
2NVTSNavitas Semiconductor78.1%310.6%
3SSIISS Innovations International40.1%23.4%
4FLNCFluence Energy40.0%15.4%
5BTDRBitdeer Technologies35.1%10.8%
6MVSTMicrovast34.6%181.6%
7POWIPower Integrations31.3%-25.4%
8CCOClear Channel Outdoor30.8%24.1%
9IRONDisc Medicine28.7%41.9%
10BEBloom Energy28.4%402.0%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1SOCSable Offshore-35.8%-48.4%
2SRRKScholar Rock-29.2%-35.4%
3AIVApartment Investment & Management-28.3%-9.0%
4ALABAstera Labs-22.5%20.6%
5BYRNByrna Technologies-19.7%-26.6%
6BWINBaldwin Insurance-19.5%-40.3%
7ONDSOndas-17.5%197.3%
8URGUr-Energy-17.4%40.0%
9IIINInsteel Industries-16.4%14.6%
10LIFLife360-16.0%112.3%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Eli Lilly

Financials

LLYMRKPFEBMYBDXBGMMedian
NameEli LillyMerck Pfizer Bristol-.Becton D.BGM  
Mkt Price802.8384.7924.5143.63189.109.1864.21
Mkt Cap720.9212.8139.388.654.3-139.3
Rev LTM53,25863,61663,83347,63621,386-53,258
Op Inc LTM22,88219,82116,6637,8702,955-16,663
FCF LTM-5014,72212,43813,0862,550-12,438
FCF 3Y Avg-15612,8999,30412,2252,504-9,304
CFO LTM10,93818,53415,18814,3103,254-14,310
CFO 3Y Avg7,23016,76612,58413,4193,278-12,584

Growth & Margins

LLYMRKPFEBMYBDXBGMMedian
NameEli LillyMerck Pfizer Bristol-.Becton D.BGM  
Rev Chg LTM36.8%1.8%13.5%4.6%7.9%-7.9%
Rev Chg 3Y Avg23.4%3.7%-12.4%0.5%4.1%-3.7%
Rev Chg Q37.6%-1.9%10.3%-5.6%10.4%-10.3%
QoQ Delta Rev Chg LTM8.7%-0.5%2.2%-1.4%2.5%-2.2%
Op Mgn LTM43.0%31.2%26.1%16.5%13.8%-26.1%
Op Mgn 3Y Avg35.6%22.6%20.2%17.3%13.3%-20.2%
QoQ Delta Op Mgn LTM1.8%-0.8%1.8%4.3%0.9%-1.8%
CFO/Rev LTM20.5%29.1%23.8%30.0%15.2%-23.8%
CFO/Rev 3Y Avg17.8%27.2%18.8%28.9%16.3%-18.8%
FCF/Rev LTM-0.1%23.1%19.5%27.5%11.9%-19.5%
FCF/Rev 3Y Avg0.5%20.9%13.8%26.4%12.4%-13.8%

Valuation

LLYMRKPFEBMYBDXBGMMedian
NameEli LillyMerck Pfizer Bristol-.Becton D.BGM  
Mkt Cap720.9212.8139.388.654.3-139.3
P/S13.53.32.21.92.5-2.5
P/EBIT40.610.410.410.921.7-10.9
P/E52.213.013.016.434.3-16.4
P/CFO65.911.59.26.216.7-11.5
Total Yield2.6%11.5%12.9%11.7%5.1%-11.5%
Dividend Yield0.7%3.8%5.2%5.5%2.2%-3.8%
FCF Yield 3Y Avg0.1%5.1%5.7%12.4%4.1%-5.1%
D/E0.10.20.40.60.4-0.4
Net D/E0.10.10.30.40.3-0.3

Returns

LLYMRKPFEBMYBDXBGMMedian
NameEli LillyMerck Pfizer Bristol-.Becton D.BGM  
1M Rtn6.8%4.0%2.0%-1.8%1.1%-7.6%1.5%
3M Rtn4.3%7.1%0.2%-6.6%6.3%-18.7%2.2%
6M Rtn-4.0%10.9%14.8%-9.0%-3.7%-16.6%-3.9%
12M Rtn-11.9%-19.1%-10.2%-13.9%-20.8%19.7%-12.9%
3Y Rtn150.2%-0.2%-32.7%-29.2%-10.6%--10.6%
1M Excs Rtn4.7%3.5%1.0%-3.5%-0.1%-8.6%0.5%
3M Excs Rtn-0.1%2.3%-4.7%-11.0%2.8%-19.3%-2.4%
6M Excs Rtn-30.2%-15.3%-11.4%-35.1%-29.9%-42.7%-30.0%
12M Excs Rtn-26.0%-35.8%-25.5%-27.8%-34.8%6.2%-26.9%
3Y Excs Rtn67.3%-83.7%-117.5%-114.4%-96.1%--96.1%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/1/20252/19/202510/30/20248/8/20244/30/20242/21/202411/2/20238/8/20234/27/20232/22/202311/1/2022
Key Financials Quarterly            
Total Revenue15,55812,72813,53311,43911,3038,7689,3539,4998,3126,9607,3026,942
Ebitda7,5044,1635,7482,2484,1153,1163,0359632,5761,9952,5552,010
Operating Income7,1265,4085,7984,5504,4182,7363,1933,5412,3381,7152,2082,038
Net Income5,6602,7594,4109702,9672,2432,190-571,7631,3451,9381,452
EPS6.303.074.911.083.292.492.43-0.061.961.492.041.61
Key Financials TTM            
Total Revenue TTM53,25849,00345,04340,86338,92335,93234,12432,07229,51627,69128,54129,240
Ebitda TTM19,66316,27415,22812,51411,2299,6898,5688,0889,1368,0818,6608,472
Operating Income TTM22,88220,17417,50214,89713,88811,80810,7879,8028,2987,7058,6538,978
Net Income TTM13,80011,10610,5908,3707,3426,1385,2404,9886,4985,6876,2456,033
Growth Rates Quarterly            
Total Revenue Growth37.6%45.2%44.7%20.4%36.0%26.0%28.1%36.8%28.1%-10.9%-8.7%2.5%
EBITDA Growth82.3%33.6%89.4%133.5%59.8%56.2%18.8%-52.1%69.3%-22.5%8.0%17.5%
Operating Income Growth61.3%97.7%81.6%28.5%89.0%59.5%44.6%73.8%34.0%-35.6%-12.8%-4.4%
Net Income Growth90.8%23.0%101.4%1790.4%68.3%66.8%13.0%-104.0%85.1%-29.3%12.3%30.8%
Margins Quarterly            
EBITDA Margin48.2%32.7%42.5%19.7%36.4%35.5%32.4%10.1%31.0%28.7%35.0%29.0%
Operating Income Margin45.8%42.5%42.8%39.8%39.1%31.2%34.1%37.3%28.1%24.6%30.2%29.4%
Net Income Margin36.4%21.7%32.6%8.5%26.3%25.6%23.4%-0.6%21.2%19.3%26.5%20.9%
Cash & Debt            
Total Cash3,5463,2213,4233,5183,3642,5862,9282,4942,8293,6692,2122,742
Total Debt39,90438,51633,64431,12028,89226,21125,22520,16818,82018,88416,23915,888
Net Debt / (Cash)36,35835,29530,22127,60125,52823,62522,29817,67415,99115,21414,02713,146
Cash Flows Quarterly            
FCF from Operations3,0871,6662,4743,7121,4661,166-3122,1906321,7311,6632,217
Cash Flows TTM            
FCF from Operations TTM10,9389,3188,8186,0324,5103,6764,2406,2156,2426,7937,5868,185
Returns to Shareholders Quarterly            
Dividends1,3471,3461,1681,1701,1721,1691,0181,0161,0181,017884882
Share Repurchases6921,2002,054446-0-0-0-0-0750-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC64.0%48.1%65.9%39.4%57.6%40.6%49.1%76.4%47.4%38.4%56.0%57.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM50.3%45.9%47.4%43.6%43.8%40.2%38.0%42.9%44.5%44.4%54.4%62.8%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Trulicity7,1327,4406,4725,0684,128
Mounjaro5,1634820  
Verzenio3,8632,4841,350913580
Taltz2,7602,4822,2131,7881,366
Jardiance2,7452,0661,4911,154944
Zyprexa1,695337430406419
Humalog1,6632,0612,4532,6262,821
Other1,1221,496370  
Cyramza9759711,0331,033925
Olumiant9238301,115639427
Humulin8521,0191,2221,2601,290
Other Oncology8301,352331  
Basaglar7287608921,1241,113
Emgality678651577363162
Baqsimi678139113  
Erbitux596566548536543
Other cardiometabolic health530497544  
Other Neuroscience506558891  
Tyvyt393293418309 
Zepbound17600  
Other Immunology1153233  
COVID-19 Antibodies02,0242,239871 
Alimta  2,0612,3302,116
Cialis  718607890
Forteo  8021,0461,405
Cymbalta   768725
Other products   1,3401,874
Trajenta   358591
Total34,12428,54228,31824,54022,320


Price Behavior

LLY Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta1.530.260.620.690.670.59
Up Beta-0.73-1.32-0.990.310.290.44
Down Beta1.82-3.03-2.010.750.680.67
Up Capture171%149%151%94%82%43%
Bmk +ve Days13233574144420
Stock +ve Days13263974138419
Down Capture215%194%250%141%112%82%
Bmk -ve Days8192952107330
Stock -ve Days8162552113332

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity7,686,850
Short Interest: % Change Since 91520255.0%
Average Daily Volume4,007,818
Days-to-Cover Short Interest1.92
Basic Shares Quantity897,900,000
Short % of Basic Shares0.9%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/2025-14.1%-11.5%-2.4%
5/1/2025-11.7%-13.6%-17.8%
1/14/2025-6.6%-6.9%9.5%
10/30/2024-6.3%-10.8%-12.6%
8/8/20249.5%20.7%17.1%
4/30/20246.0%4.0%10.3%
2/6/2024-0.2%4.4%10.6%
11/2/20234.7%11.7%5.5%
...
SUMMARY STATS   
# Positive101215
# Negative13118
Median Positive4.0%4.9%7.2%
Median Negative-3.5%-4.6%-7.1%
Max Positive14.9%20.7%23.6%
Max Negative-14.1%-13.6%-17.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024219202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024808202410-Q 6/30/2024
3312024430202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023808202310-Q 6/30/2023
3312023427202310-Q 3/31/2023
12312022222202310-K 12/31/2022
93020221101202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021223202210-K 12/31/2021
93020211027202110-Q 9/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.